Recent Updates
Recently added Catalysts
RIGL Positive Sentiment

Rigel to Present at the Jefferies London Healthcare Conference

Tuesday, November 12, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Rigel Pharmaceuticals, Inc. announced that its CFO, Dean Schorno, will present an overview at the Jefferies London Healthcare Conference on November 19, 2024. This event showcases Rigel's commitment to engaging with stakeholders and providing insights into its business strategy and pipeline. Investors can access the live webcast through the company's website, emphasizing transparency in communications. Rigel continues to focus on developing novel therapies for hematologic disorders and cancer.
Price reaction · baseline $24.95 (2024-11-11 close) · hit after-hours · clean, no other RIGL news in the window
day 0 close
+9.1%
day 1 · peak
+9.9%
day 3
-3.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Rigel's presentation at a significant healthcare conference indicates confidence in their business strategy.
  • The company's focus on hematologic disorders and cancer aligns with urgent medical needs.
  • Access to the live webcast demonstrates transparency and investor engagement.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+9%
120-day peak, hindsight
Typical move
12.1%
average across 2 past catalysts
Lead asset
Fostamatinib
Phase 2 · Acute Respiratory Distress Syndrome

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will present a company overview at the Jefferies London Healthcare Conference on Tuesday, November 19, at 9:30 am GMT (4:30 am EST).
To access the live webcast or archived recording, visit the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website prior to the start of the live webcast to allow for any software downloads.
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com.
Contact for Investors & Media:
Rigel Pharmaceuticals, Inc.

Frequently Asked Questions

When will Rigel Pharmaceuticals present at the Jefferies Conference?

Rigel Pharmaceuticals will present on November 19 at 9:30 am GMT.

Who is presenting for Rigel Pharmaceuticals at the conference?

Dean Schorno, the CFO of Rigel Pharmaceuticals, will present.

How can I access Rigel's conference presentation?

Access the live webcast or recording via the Investor Relations section on Rigel's website.

What does Rigel Pharmaceuticals focus on?

Rigel focuses on hematologic disorders and cancer therapies.

Where is Rigel Pharmaceuticals located?

Rigel Pharmaceuticals is based in South San Francisco, California.

ShareAdd on Google
Tags: RIGL Viatris Investor Conferences Healthcare Jefferies Conference biotechnology haematologic disorders cancer therapies
Last updated: Nov 12, 2024

Biotech snapshot

Cash runway
$95M liquidity · $0M/mo burn
Low dilution risk
Lead asset
FostamatinibPhase 2
Acute Respiratory Distress Syndrome →

Catalyst track record

+9%
best trade around RIGL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for RIGL.

See every catalyst's timing & PoA →